Add-on Acquisition • Life Science

ProKidney Acquires inRegen

On January 14, 2019, ProKidney acquired life science company inRegen for 62M USD

Acquisition Context

This is ProKidney’s 1st transaction in the Life Science sector.
This is ProKidney’s largest (disclosed) transaction.
This is ProKidney’s 1st transaction in the United States.
This is ProKidney’s 1st transaction in New York.

Explore All 3109 Add-on Acquisition Life Science Deals - Search the Database Free

M&A Deal Summary
Date	January 14, 2019
Target	inRegen
Sector	Life Science
Buyer(s)	ProKidney
Deal Type	Add-on Acquisition
Deal Value	62M USD

Target Company

inRegen

New York, United States

inRegen is a biotechnology company focused on developing advanced cellular therapies for treating chronic kidney disease (CKD). The company is based on over 14 years of proprietary breakthroughs in progenitor cell biology research, development, and manufacturing. It produces a personalized autologous cell therapy, by using the patient's own cells and proprietary methods of manufacturing.

Explore More Deals

Browse All 215,130 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

ProKidney

New York, New York, United States

Category	Company
Sector	Life Science

DESCRIPTION

ProKidney LLC is a biotechnology company founded by a group of investors led by Pablo Legorreta.

Deal Context for Buyer	#
Overall	1 of 1
Sector: Life Science	1 of 1
Type: Add-on Acquisition	1 of 1
State: New York	1 of 1
Country: United States	1 of 1
Year: 2019	1 of 1
Size (of disclosed)	1 of 1

Explore Related M&A Activity

Life Science M&A - Add-on Acquisition M&A Deals - New York M&A - United States M&A - 2019 M&A